The phase 3 NRG-GU005 trial compared moderately hypofractionated IMRT in 20 to 28 sessions vs SBRT in 5 sessions for efficacy and health-related quality-of-life in men with favorable intermediate-risk ...
Neoadjuvant SBRT and Immunotherapy Show Potential in High-Risk ER+/HER2− Breast Cancer / Adinda Baten, Alex De Caluwe, Andrea Joaquín García, Breast Cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results